Barclays PLC Immuneering Corp Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Immuneering Corp stock. As of the latest transaction made, Barclays PLC holds 9,924 shares of IMRX stock, worth $20,244. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,924
Previous 9,924
-0.0%
Holding current value
$20,244
Previous $25,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding IMRX
# of Institutions
41Shares Held
4.64MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.07MShares$2.18 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD810KShares$1.65 Million0.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$1.09 Million0.0% of portfolio
-
Morgan Stanley New York, NY449KShares$916,5940.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny246KShares$502,3900.0% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $53.8M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...